Pharmacogenetics of adverse reactions to antiepileptic drugs

López-López, 2004, Farmacogenómica: búsqueda de la terapia personalizada, Rev Neurol, 39, 1063 Roden, 2002, The genetic basis of variability in drug responses, Nat Rev Drug Discov, 1, 37, 10.1038/nrd705 Lazarou, 1998, Incidence of adverse drug reactions in hospitalized patients, JAMA, 279, 1200, 10.1001/jama.279.15.1200 Pirmohamed, 2004, Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients, BMJ, 329, 15, 10.1136/bmj.329.7456.15 Wester, 2007, Incidence of fatal adverse drug reactions: a population based study, Br J Clin Pharmacol, 65, 573, 10.1111/j.1365-2125.2007.03064.x Budnitz, 2011, Emergency hospitalizations for adverse drug events in older Americans, N Engl J Med, 365, 2002, 10.1056/NEJMsa1103053 Chan, 2008, Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: a prospective, descriptive, observational study, Curr Therap Res, 69, 118, 10.1016/j.curtheres.2008.04.005 Morimoto, 2004, Adverse drug events and medication errors: detection and classification methods, Qual Saf Health Care, 13, 306, 10.1136/qshc.2004.010611 Suh, 2000, Clinical an economic impact of adverse drug reactions in hospitalized patients, Ann Pharmacother, 34, 1373, 10.1345/aph.10094 1972, International drug monitoring: the role of national centers Report of a WHO meeting, World Health Organ Tech Rep Ser, 498, 1 Edwards, 2000, Adverse drug reactions: definitions, diagnosis, and management, Lancet, 356, 1255, 10.1016/S0140-6736(00)02799-9 Scott, 2011, Adverse drug reactions, Anaesth Intensive Care, 12, 319, 10.1016/j.mpaic.2011.04.010 Perucca, 2012, Adverse effects of antiepileptic drugs, Lancet Neurol, 11, 792, 10.1016/S1474-4422(12)70153-9 Bruno, 2013, Epilepsy and neurocysticercosis in Latin America: a systematic review and meta-analysis, PLoS Negl Trop Dis, 7, e2480, 10.1371/journal.pntd.0002480 Ngugi, 2010, Estimation of the burden of active and life-time epilepsy: a meta-analytic approach, Epilepsia, 51, 883, 10.1111/j.1528-1167.2009.02481.x Brogden, 1980, Clobazam. A review of its pharmacological properties and therapeutic use in anxiety, Drugs, 20, 161, 10.2165/00003495-198020030-00001 Greenwood, 2000, Adverse effects of antiepileptic drugs, Epilepsia, 41, S42, 10.1111/j.1528-1157.2000.tb01523.x Herranz, 1988, Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children, Epilepsia, 29, 794, 10.1111/j.1528-1157.1988.tb04237.x Hill, 2010, Teratogenic effects of antiepileptic drugs, Expert Rev Neurother, 10, 943, 10.1586/ern.10.57 Jarernsiripornkul, 2012, Patient reporting of suspected adverse drug reactions to antiepileptic drugs: factors affecting attribution accuracy, Epilepsy Behav, 24, 102, 10.1016/j.yebeh.2012.03.023 Ketter, 1999, Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders, Neurology, 53, S53 Massot, 2014, Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results, Neurología, 29, 94, 10.1016/j.nrl.2013.02.013 Pellock, 1987, Carbamazepine side effects in children and adults, Epilepsia, 28, S64, 10.1111/j.1528-1157.1987.tb05780.x Posner, 2005, A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine, Seizure, 14, 117, 10.1016/j.seizure.2004.12.003 Tomson, 2013, Efectos teratogénicos de fármacos antiepilépticos, Neurol Arg, 5, 49 Riverol, 2009, Avances en el tratamiento de la epilepsia, Medicine, 10, 3091 Zaccara, 2008, Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies, Seizure, 17, 405, 10.1016/j.seizure.2007.12.003 Zaccara, 2011, The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials, Epilepsia, 52, 826, 10.1111/j.1528-1167.2010.02966.x Zaccara, 2013, The adverse event profile of perampanel: meta-analysis of randomized controlled trials, Eur J Neurol, 20, 1204, 10.1111/ene.12170 Zaccara, 2013, Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine, Seizure, 22, 528, 10.1016/j.seizure.2013.03.016 Zaccara, 2013, The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials, Epilepsia, 54, 66, 10.1111/j.1528-1167.2012.03589.x Perucca, 2009, Adverse antiepileptic drug effects. Toward a clinically and neurobiologically relevant taxonomy, Neurology, 72, 1223, 10.1212/01.wnl.0000345667.45642.61 Cramer, 1999, New antiepileptic drugs: comparison of key clinical trials, Epilepsia, 40, 590, 10.1111/j.1528-1157.1999.tb05561.x Kwan, 2000, Early identification of refractory epilepsy, N Engl J Med, 342, 314, 10.1056/NEJM200002033420503 Gilliam, 2004, Tolerability of antiseizure medications. Implications for health outcomes, Neurology, 63, S9, 10.1212/WNL.63.10_suppl_4.S9 De Kinderen, 2014, Side-effects of antiepileptic drugs: the economic burden, Seizure, 23, 184, 10.1016/j.seizure.2013.11.009 Madian AG, Baker Jones R. Variable drug response: genetic evaluation. In: Cooper DN, editor. Encyclopedia of life sciences (eLS). Genetics & Disease. Chichester: John Wiley & Sons Ltd; 2013. Available from: http://www.els.net http://dx.doi.org/10.1002/9780470015902.a0006001.pub2 Evans, 2003, Pharmacogenomics-drug disposition, drug targets and side effects, N Engl J Med, 348, 538, 10.1056/NEJMra020526 Kalow, 1998, Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research, Pharmacogenetics, 8, 283, 10.1097/00008571-199808000-00001 Weisenhilboum, 2003, Inheritance and drug response, N Engl J Med, 348, 529, 10.1056/NEJMra020021 Zaccara, 2007, Idiosyncratic adverse reactions to antiepielptic drugs, Epilepsia, 48, 1223, 10.1111/j.1528-1167.2007.01041.x Anderson, 2004, Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs, Neurology, 63, S3, 10.1212/WNL.63.10_suppl_4.S3 Llerena, 2004, Lower frequency of CYP2 C9*2 in Mexican-Americans compared to Spaniards, Pharmacogenomics J, 4, 403, 10.1038/sj.tpj.6500278 Sullivan-Klose, 1996, The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism, Pharmacogenetics, 6, 341, 10.1097/00008571-199608000-00007 Dorado, 2011, CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards, Pharmacogenomics J, 11, 108, 10.1038/tpj.2010.29 Sosa-Macías, 2013, Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico, Pharmacogenomics J, 13, 567, 10.1038/tpj.2012.52 Dickmann, 2001, Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans, Mol Pharmacol, 60, 382, 10.1124/mol.60.2.382 Kidd, 2001, Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin, Pharmacogenetics, 11, 803, 10.1097/00008571-200112000-00008 Depondt, 2011, A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity, Eur J Neurol, 18, 1159, 10.1111/j.1468-1331.2011.03361.x Dorado, 2013, Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9 CYP2 C19 and ABCB1 genetic polymorphisms, Pharmacogenomics J, 13, 359, 10.1038/tpj.2012.19 Babu, 2013, Charles C Cytochrome P450 2C9 gene polymorphism in phenytoin induced gingival enlargement: a case report, J Pharm Bioallied Sci, 5, 237, 10.4103/0975-7406.116828 Ninomiya, 2000, Genetic polymorphism of the CYP2 C subfamily and excessive serum phenytoin concentration with central nervous system intoxication, Ther Drug Monit, 22, 230, 10.1097/00007691-200004000-00016 Ramasamy, 2007, Severe phenytoin toxicity in a CYP2 C9*3*3 homozygous mutant from India, Neurol India, 55, 408, 10.4103/0028-3886.33300 Pharmgkb Dutch Pharmacogenetics working group guideline for phenytoin and CYP2C9 (2011). Available from: http://www.pharmgkb.org/guideline/PA166104984 [accessed 07.06.14]. Goldstein, 2001, Clinical relevance of genetic polymorphisms in the human CYP2 C subfamily, Br J Clin Pharmacol, 52, 349, 10.1046/j.0306-5251.2001.01499.x Mamiya, 1998, The effects of genetic polymorphisms of CYP2C9 and CYP2 C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics, Epilepsia, 39, 1317, 10.1111/j.1528-1157.1998.tb01330.x Thorn, 2012, PharmGKB summary: phenytoin pathway, Pharmacogenet Genomics, 22, 466, 10.1097/FPC.0b013e32834aeedb Dennery, 2007, Effects of oxidative stress on embryonic development, Birth Defect Res C Embryo Today, 81, 155, 10.1002/bdrc.20098 Azzato, 2010, Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations, Pharmacogenet Genomics, 20, 58, 10.1097/FPC.0b013e328334b6a3 Kalapos, 2002, Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation, Adverse Drug React Toxicol Rev, 21, 123, 10.1007/BF03256188 Ueda, 2007, Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity, Pharmacogenomics, 8, 435, 10.2217/14622416.8.5.435 Fukushima, 2008, Glutathione-S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes are risk factors for increased serum γ-glutamyltransferase in valproic acid-treated patients, Clin Chim Acta, 389, 98, 10.1016/j.cca.2007.11.035 Guillemette, 2003, Pharmacogenomics of human UDP glucuronosyltransferase enzymes, Pharmacogenomics J, 3, 136, 10.1038/sj.tpj.6500171 Saruwatari, 2010, Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy, Pharmaceuticals, 3, 2709, 10.3390/ph3082709 Gulcebi, 2011, The relationship between UGT1 A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy, Epilepsy Res, 95, 1, 10.1016/j.eplepsyres.2011.01.016 Chu, 2012, Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients, Eur J Clin Pharmacol, 68, 1395, 10.1007/s00228-012-1277-7 Munisamy, 2013, The effect of uridine diphosphate glucuronosyltransferase (UGT)1 A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach, Mol Diagn Ther, 17, 319, 10.1007/s40291-013-0041-8 Jones, 2004, The ABC transporter structure and mechanism: perspectives on recent research, Cell Mol Life Sci, 61, 682, 10.1007/s00018-003-3336-9 Dombrowski, 2001, Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy, Epilepsia, 42, 1501, 10.1046/j.1528-1157.2001.12301.x Potschka, 2003, Multidrug resistance protein MRP2 contributes to blood–brain barrier function and restricts antiepileptic drug activity, J Pharmacol Exp Ther, 306, 124, 10.1124/jpet.103.049858 Yi, 2013, Genetic variations of ABCC2 gene associated with adverse drug reactions to valproic acid in Korean epileptic patients, Genomics Inform, 11, 254, 10.5808/GI.2013.11.4.254 Kim, 2009, Lack of association between ABCB1, ABCG2 and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy, Epilepsy Res, 84, 86, 10.1016/j.eplepsyres.2008.12.001 Seo, 2008, ABCC2 haplotype is not associated with drug-resistant epilepsy, J Pharm Pharmacol, 60, 631, 10.1211/jpp.60.5.0009 Kim, 2010, A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy, Pharmacogenet Genomics, 20, 249, 10.1097/FPC.0b013e328338073a Choi, 2007, MRP2 haplotypes confer differential susceptibility to toxic liver injury, Pharmacogenet Genomics, 17, 403, 10.1097/01.fpc.0000236337.41799.b3 Luna-Tortós, 2008, Several major antiepileptic drugs are substrates for human P-glycoprotein, Neuropharmacology, 55, 1364, 10.1016/j.neuropharm.2008.08.032 Hoffmeyer, 2000, Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc Natl Acad Sci U S A, 97, 3473, 10.1073/pnas.97.7.3473 Hung, 2008, Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs, Pharmacogenet Genomics, 18, 390, 10.1097/FPC.0b013e3282f85e36 Szoeke, 2006, Update on pharmacogenetics in epilepsy: a brief review, Lancet Neurol, 5, 189, 10.1016/S1474-4422(06)70352-0 Stern, 2012, Exanthematous drug eruptions, N Engl J Med, 366, 2492, 10.1056/NEJMcp1104080 McCormack, 2011, HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans, N Engl J Med, 364, 1134, 10.1056/NEJMoa1013297 Eshki, 2009, Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms. A cause of unpredictable multiorgan failure, Arch Dermatol, 145, 67, 10.1001/archderm.145.1.67 Shiohara, 2006, Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses, Allergol Int, 55, 1, 10.2332/allergolint.55.1 Aihara, 2011, Pharmacogenetics of cutaneous adverse drug reactions, J Dermatol, 38, 246, 10.1111/j.1346-8138.2010.01196.x Rzany, 1996, Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry, J Clin Epidemol, 49, 769, 10.1016/0895-4356(96)00035-2 Bastuji-Garin, 1993, Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, Arch Dermatol, 129, 92, 10.1001/archderm.1993.01680220104023 Roujeau, 1997, Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme, J Dermatol, 24, 726, 10.1111/j.1346-8138.1997.tb02524.x Goyal, 2009, Toxic epidermal necrolysis in children: medical surgical, and ophthalmologic considerations, J Burn Care Res, 30, 437, 10.1097/BCR.0b013e3181a28c82 Magina, 2003, Dermatological and ophthalmological sequels in toxic epidermal necrolysis, Dermatology, 207, 33, 10.1159/000070938 Schnyder, 2009, Mechanisms of drug-induced allergy, Mayo Clin Proc, 84, 268, 10.4065/84.3.268 Naisbitt, 2000, Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment, Drug Saf, 23, 483, 10.2165/00002018-200023060-00002 Pichler, 2006, Pharmacological interaction of drugs with immune receptors: the p-i concept, Allergol Int, 55, 17, 10.2332/allergolint.55.17 Barquera, 2008, HLA class I and class II haplotypes in admixed families from several regions of Mexico, Mol Immunol, 45, 1171, 10.1016/j.molimm.2007.07.042 Granados-Arriola, 2012, Inmunogenética del complejo principal de histocompatibilidad, 445 Chung, 2004, Medical genetics: a marker for Stevens-Johnson syndrome, Nature, 428, 486, 10.1038/428486a Hung, 2006, Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions, Pharmacogenet Genom, 16, 297, 10.1097/01.fpc.0000199500.46842.4a Man, 2007, Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese, Epilepsia, 48, 1015, 10.1111/j.1528-1167.2007.01022.x Wang, 2011, Influence of chemical structure on skin reactions induced by antiepileptic drugs—the role of the aromatic ring, Epilepsy Res, 94, 213, 10.1016/j.eplepsyres.2011.02.005 Tangamornsukan, 2013, Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis, JAMA Dermatol, 149, 1025, 10.1001/jamadermatol.2013.4114 Carbamazepine (marketed as carbatrol, equetro, tegreto and generics) FDA, US Food and Drug Administration. 2007. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150841.htm. Lonjou, 2006, A marker for Stevens-Johnson syndrome…: ethnicity matters, Pharmacogenomics J, 6, 265, 10.1038/sj.tpj.6500356 Ueta, 2008, HLA class i and ii gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese, Mol Vis, 14, 550 Kaniwa, 2010, HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in japanese patients, Epilepsia, 51, 2461, 10.1111/j.1528-1167.2010.02766.x McCormack, 2012, Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions, Pharmacogenomics, 13, 399, 10.2217/pgs.11.165 Ozeki, 2011, Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population, Hum Mol Genet, 20, 1034, 10.1093/hmg/ddq537 Li, 2013, Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese, Epilepsy Res, 106, 296, 10.1016/j.eplepsyres.2013.05.004 Hung, 2010, Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, Pharmacogenomics, 11, 349, 10.2217/pgs.09.162 Pirmohamed, 2001, TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients, Neurology, 56, 890, 10.1212/WNL.56.7.890 Ikeda, 2010, HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions, Epilepsia, 51, 297, 10.1111/j.1528-1167.2009.02269.x